Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating

Core Viewpoint - Arcutis Biotherapeutics has received a stock rating upgrade, achieving a Relative Strength Rating of 82, indicating strong market performance potential [1][3]. Company Performance - Arcutis recently obtained its sixth FDA approval for a dermatology drug aimed at treating children's skin diseases, specifically dermatitis [2][3]. - The newly approved Zoryve cream is steroid-free and has been reported as "safe and well-tolerated" for children as young as two years old [3]. - The company reported a 244% increase in earnings to $0.13 per share last quarter, alongside an 81% rise in revenue to $129.5 million [4]. Stock Ratings and Market Position - Arcutis holds an 83 Composite Rating, placing it in the top 17% of stocks across all industries for price performance over the past year [3]. - The stock has a D- Accumulation/Distribution Rating, indicating that large funds are selling more shares than they are buying, despite strong fundamentals [4]. - The stock price has more than doubled from a low of $11.13 per share in early February last year to $22.38, although it experienced a 1.6% decline on the latest trading day [6]. Historical Performance - Arcutis stock reached a 52-week high of $31.77 on December 8, 2022, marking its highest price since May 2021 [7]. - The stock has shown consistent earnings growth over the past year, with quarterly EPS gains of 38%, 69%, and 118% prior to the latest quarter [4]. Industry Ranking - Arcutis ranks No. 61 among its peers in the 647-stock Medical-Biomed/Biotech industry group [8].